The Belt and Road: Cooperation, Harmony and Win-Win
products

Products

Linagliptin CAS:668270-12-0 Manufacturer Supplier

Linagliptin (trade names Tradjenta and Trajetna) is an inhibitor of dipeptidyl peptidase-4 (DPP-4) that was approved by the U.S. FDA in May 2011 for the treatment of Type 2 diabetes along with diet and exercise. Linagliptin (BI-1356) has been described as a potent highly selective, slow-off rate and long acting inhibitor of DPP-4. Linagliptin arose from optimization efforts of xanthine-based DPP-4 inhibitors with the initial lead identified from an HTS campaign.


Product Detail

Product Tags

Application and Effect

Linagliptin (TrajentaR, TradjentaTM, TrazentaTM, TrayentaTM) is an oral, highly selective inhibitor of dipeptidyl peptidase-4 and is the first agent of its class to be eliminated predominantly via a nonrenal route. Linagliptin is indicated for once daily use for the treatment of adults with type 2 diabetes mellitus.Linagliptin acts to lower blood glucose levels by inhibiting the enzyme DPP-4, thereby preventing the degradation of the incretin hormones (glucagon-like peptide-1 [GLP-1] and glucose-dependent insulinotropic peptide) and attenuating postprandial glucose excursions.

Product Sample

图片285(1)
图片286(1)

Product Packing:

图片202(1)

Additional Information:

Composition C25H28N8O2
Assay 99%
Appearance White powder
CAS No. 668270-12-0
Packing 25KG
Shelf Life 2 years
Storage Store in cool and dry area
Certification ISO.

  • Previous:
  • Next:

  • Write your message here and send it to us